<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Wang Y</submitter><funding>Cancer Research UK</funding><funding>The Francis Crick Institute</funding><funding>Medical Research Council</funding><funding>Wellcome Trust</funding><pagination>2554-61</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC4806223</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>14(11)</volume><pubmed_abstract>Cockayne syndrome (CS) is a severe neurodevelopmental disorder characterized by growth abnormalities, premature aging, and photosensitivity. Mutation of Cockayne syndrome B (CSB) affects neuronal gene expression and differentiation, so we attempted to bypass its function by expressing downstream target genes. Intriguingly, ectopic expression of Synaptotagmin 9 (SYT9), a key component of the machinery controlling neurotrophin release, bypasses the need for CSB in neuritogenesis. Importantly, brain-derived neurotrophic factor (BDNF), a neurotrophin implicated in neuronal differentiation and synaptic modulation, and pharmacological mimics such as 7,8-dihydroxyflavone and amitriptyline can compensate for CSB deficiency in cell models of neuronal differentiation as well. SYT9 and BDNF are downr</pubmed_abstract><journal>Cell reports</journal><pubmed_title>Pharmacological Bypass of Cockayne Syndrome B Function in Neuronal Differentiation.</pubmed_title><pmcid>PMC4806223</pmcid><funding_grant_id>10166</funding_grant_id><funding_grant_id>11567</funding_grant_id><pubmed_authors>Muotri A</pubmed_authors><pubmed_authors>Chakravarty P</pubmed_authors><pubmed_authors>Laposa RR</pubmed_authors><pubmed_authors>Svejstrup JQ</pubmed_authors><pubmed_authors>Jones-Tabah J</pubmed_authors><pubmed_authors>Stewart A</pubmed_authors><pubmed_authors>Wang Y</pubmed_authors></additional><is_claimable>false</is_claimable><name>Pharmacological Bypass of Cockayne Syndrome B Function in Neuronal Differentiation.</name><description>Cockayne syndrome (CS) is a severe neurodevelopmental disorder characterized by growth abnormalities, premature aging, and photosensitivity. Mutation of Cockayne syndrome B (CSB) affects neuronal gene expression and differentiation, so we attempted to bypass its function by expressing downstream target genes. Intriguingly, ectopic expression of Synaptotagmin 9 (SYT9), a key component of the machinery controlling neurotrophin release, bypasses the need for CSB in neuritogenesis. Importantly, brain-derived neurotrophic factor (BDNF), a neurotrophin implicated in neuronal differentiation and synaptic modulation, and pharmacological mimics such as 7,8-dihydroxyflavone and amitriptyline can compensate for CSB deficiency in cell models of neuronal differentiation as well. SYT9 and BDNF are downr</description><dates><release>2016-01-01T00:00:00Z</release><publication>2016 Mar</publication><modification>2026-05-04T08:53:14.961Z</modification><creation>2019-03-27T03:10:12Z</creation></dates><accession>S-EPMC4806223</accession><cross_references><pubmed>26972010</pubmed><doi>10.1016/j.celrep.2016.02.051</doi></cross_references></HashMap>